Kisspeptin dosage, as reported in the research literature.

The short version

This page describes Kisspeptin dosage the way the studies describe it — and only that way. There is no approved kisspeptin product and no standard dose, so nothing here is a recommendation, and you will not find a "how much to take" number. Every figure is what researchers gave to a specific group of people, by a specific route, under supervision.

Two facts shape all of it. First, the two main forms behave differently: kisspeptin-10 clears from the blood in minutes, while kisspeptin-54 lasts roughly half an hour, so they are dosed differently. Second, tachyphylaxis — give it continuously or too often and the receptor stops responding within days. Because of that, short, well-spaced exposures preserve the response better than continuous infusion. Routes studied include intravenous, under-the-skin injection, and, most recently, a nasal spray.

Kisspeptin dosage as studied (by population and route)

The research doses below are documented protocols, reported as studied at X in a stated population by a stated route — never as instructions. In early human work, kisspeptin-54 was given by IV infusion at 4 pmol/kg/min over 90 minutes. In healthy men, kisspeptin-10 was studied as an IV bolus at 0.3-1.0 ug/kg and as a continuous infusion at 1.5 ug/kg/h, with the 1 ug/kg bolus producing maximal LH stimulation ^[3]. In women with hypothalamic amenorrhea, kisspeptin-54 was infused IV at 0.01-1.00 nmol/kg/h to restore LH pulses ^[4]. As an IVF oocyte-maturation trigger, kisspeptin-54 was given as a single subcutaneous bolus of 3.2-12.8 nmol/kg, with 9.6 nmol/kg associated with the highest live-birth rate ^[5]. None of these is transferable to any individual.

Kisspeptin half life

The two isoforms differ sharply. Kisspeptin-10 has a functional half-life of roughly 4 minutes in humans, cleared quickly by plasma peptidases. Kisspeptin-54 lasts far longer — about 27-28 minutes (27.6 ± 1.1 min reported in early human work) — because its larger size and greater resistance to endopeptidase cleavage give it a substantially longer duration of action. That difference is why kisspeptin-10 is favored for short, sharp pulse studies and kisspeptin-54 for triggers and longer infusions ^[3]. The short functional half-life of kisspeptin-10 also means receptor sensitivity may be better preserved with well-spaced or pulsatile protocols.

Kisspeptin nasal spray

The newest delivery route is intranasal. In 2025, intranasal kisspeptin-54 at a primary dose of 12.8 nmol/kg (with 3.2, 6.4, and 25.6 nmol/kg also tested in men) rapidly stimulated LH in healthy men (+4.4 IU/L), healthy women (+1.4 IU/L), and women with hypothalamic amenorrhea (+4.4 IU/L), with no adverse events, and the nasal-spray formulation was stable for up to 60 days at 4 °C ^[6]. This was the first clinical demonstration that kisspeptin can be delivered effectively without injection — a meaningful step for any future non-invasive research use, though still investigational.

Why continuous dosing fails: tachyphylaxis

Schedule matters more than size. Chronic twice-daily subcutaneous kisspeptin-54 in women with hypothalamic amenorrhea caused marked tachyphylaxis: the acute LH increment of about 24 IU/L on day 1 fell to about 2.5 IU/L by the 14th injection day ^[16]. High-dose continuous IV infusion (1.0 nmol/kg/h) likewise showed desensitization during the infusion ^[4]. The practical reading from the literature is that pushing the dose or the duration does not reliably increase or sustain the response and can blunt it — which is exactly why the studies that work best use bolus or pulsatile, not continuous, exposure.

Stability and handling notes from the literature

Formulation stability is route-specific. The 2025 intranasal study reported the kisspeptin-54 nasal-spray formulation stable for up to 60 days at 4 °C ^[6]. Kisspeptin-10 has a shorter functional half-life owing to plasma peptidase activity. These are characteristics observed in research formulations, not handling instructions for any product — kisspeptin remains an investigational research peptide with no approved presentation.